Current practice of chronic hepatitis B treatment in Southern Italy

6533b7d8fe1ef96bd1269a54

RESEARCH PRODUCT

Current practice of chronic hepatitis B treatment in Southern Italy

T. Stroffolini Aldo Spadaro V. Di Marco G. Scifo M. Russello G. Montalto G. Bertino L. Surace B. Caroleo G. Foti V. Portelli S. Madonia M Sapienza L. Cosco P. Frugiuele A. Galdieri N. Brandolino R. Siciliano S. Bruno P. L. Almasio Carmela Morace

subject

Adult Male medicine.medical_specialty HBsAg Guanine Cirrhosis Organophosphonates Pyrimidinones Nucleosides analogues Antiviral Agents Polyethylene Glycols Young Adult Hepatitis B Chronic Chronic hepatitis Interferon Pegylated interferon Internal medicine HBV Internal Medicine medicine Humans Hepatitis B e Antigens Practice Patterns Physicians'Tenofovir Prospective cohort study Aged Aged 80 and over Telbivudine business.industry Adenine Age Factors Interferon-alpha Nucleosides Middle Aged HBV; Interferon; Nucleosides analogues; Nucleotides analogues Nucleotides analogues medicine.disease Recombinant Proteins Italy Lamivudine Current practice Immunology Interferon Female Previously treated business Thymidine medicine.drug

description

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (38.0%) patients (26 cases with Interferon or Pegylated Interferon and 68 with nucleos(t)ides analogues). As many as 49.5% of subjects with chronic hepatitis did not receive antiviral treatment. Discussion The majority of chronic HBsAg carrier referring centres for evaluation were not considered suitable for antiviral treatment. Nucleos(t)ides analogues are the preferred first choice for therapy. A long-lasting period of observation may be needed to make appropriate therapeutic decisions in several cases.

year	journal	country	edition	language
2012-01-01	European Journal of Internal Medicine

https://doi.org/10.1016/j.ejim.2012.03.018